Anavex Life Sciences Corp , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
infoAnavex Life Sciences is a small cap stock with a total market cap of 648.32M.
infoThey trade on the NASDAQ and had their IPO 17 years ago.
infoAnavex Life Sciences currently employs 38 people.
infoAs of Wednesday, Aug 23 2023, Anavex Life Sciences’s share price is $8.02.
News Relating to Anavex Life Sciences
GlobeNewsWire
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Wednesday Aug 02 2023 at 07:30
NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.
GlobeNewsWire
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Tuesday Aug 01 2023 at 07:30
Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET
Seeking Alpha
Anavex: Will Be An Interesting Endgame To Watch
Tuesday Jul 18 2023 at 11:40
Not much has happened at Anavex Life Sciences Corp. since my last coverage in March. There are a few pieces of news, which I cover here. The toplining of their pivotal trials will be an endgame I will keenly watch.
Proactive Investors
Anavex Life Sciences’ Rett syndrome treatment impresses analysts
Friday Jun 30 2023 at 13:56
Anavex Life Sciences (NASDAQ:AVXL) Corp announced earlier this week that its Rett syndrome treatment showed a disease-modifying effect in a long-term clinical trial. On news of the results, analysts at Dawson James Securities reiterated its Buy rating for the company and its price target of $39.
GlobeNewsWire
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Tuesday Jun 20 2023 at 07:30
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference taking place on June 26, 2023.
Zacks Investment Research
Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?
Thursday Jun 08 2023 at 10:52
Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
Seeking Alpha
Anavex’s Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer’s Disease
Tuesday Jun 06 2023 at 21:00
Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer’s disease. If granted accelerated approval by the FDA, Anavex’s stock value is expected to rise significantly. Anavex may provide the best investment opportunity and drug hope for the near long-term stabilization of mild Alzheimer’s disease in those with functioning sigma-1 receptors.
Zacks Investment Research
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet
Wednesday May 31 2023 at 11:00
The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here’s is How to Trade
Monday May 15 2023 at 11:26
The average of price targets set by Wall Street analysts indicates a potential upside of 342.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewsWire
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
Tuesday May 02 2023 at 07:30
Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET
GlobeNewsWire
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Tuesday Apr 25 2023 at 07:30
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.
GlobeNewsWire
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Monday Apr 10 2023 at 07:00
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other Central Nervous System (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.
Seeking Alpha
Buy Anavex For Its Likely Positive Alzheimer’s Disease Data
Thursday Mar 16 2023 at 04:06
The ANAVEX2-73-AD-004 trial was mostly positive. A reputable journal article on the missing data would allay fears of a ‘spin’.
Seeking Alpha
Anavex: Many Questions Answered, A Few Still Left, But Things Are Progressing Well
Wednesday Mar 08 2023 at 08:50
Anavex seems to have effectively handled the Rett syndrome endpoint issues. A future publication should also throw more light on the AD data.
The Motley Fool
Why Shares of Anavex Life Sciences Rose 12.4% in February
Monday Mar 06 2023 at 20:21
Anavex is a clinical-stage biotech stock with no revenue. The company’s lead therapy is being tested to treat a host of neurodegenerative and neurological conditions.
The Motley Fool
Is Anavex Life Sciences Stock a Buy Now?
Thursday Feb 23 2023 at 10:00
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
The Motley Fool
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Thursday Feb 09 2023 at 08:45
Short-sellers have piled into this clinical-stage biopharma stock.
Seeking Alpha
Anavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDA
Thursday Feb 09 2023 at 08:00
Anavex Life Sciences recently reported their Q1 2023 earnings that revealed a beat on EPS and a robust cash position that should fund the company for the next four years. The company updated investors on ANAVEX 2-73 in Alzheimer’s and publicized that they “plan to submit the data for publication and peer-reviewed medical journal in the near term”.
The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
Wednesday Feb 08 2023 at 10:16
The biotech’s shares have been steadily leaking higher following positive late-stage Alzheimer’s disease trial results.
Seeking Alpha
Anavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call Transcript
Tuesday Feb 07 2023 at 10:55
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Clint Tomlinson – IR Christopher Missling – President and CEO Sandra Boenisch – Principal Financial Officer Conference Call Participants Soumit Roy – Jones Trading Yun Zhong – BTIG Clint Tomlinson Good morning, everyone. And welcome to the Anavex Life Sciences’ Fiscal 2023 First Quarter Conference Call.
Seeking Alpha
Approval For Anavex’s Blarcamesine Looks Inevitable After Biogen’s Leqembi Approved
Monday Jan 30 2023 at 12:13
FDA grants emergency approval of Biogen/Eisai’s Leqembi (previously Lecanemab), based solely on Phase 2 trial results; Phase 3 results to be considered for final approval. Anavex Life Sciences produces the alternative Alzheimer’s drug Blarcamesine, which appears more effective, cheaper and safer than Leqembi, based on Blarcamesine’s Phase 2b/3 trial.
The Motley Fool
3 Biotech Stocks Under $15 Worth a Second Look in 2023
Wednesday Jan 18 2023 at 08:00
All three stocks have promising therapies that could drive revenue in the coming years.
Seeking Alpha
Anavex: Drug Treatments For Early Alzheimer’s Disease
Tuesday Jan 17 2023 at 17:10
Anavex 2-73/blarcamesine at high concentrations in early Alzheimer’s disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon’s ALZ-801 reduces cognitive decline in ApoE4 carriers by about the same amount as Eisai and Biogen’s Leqembi and Aduhelm, but without the risks of brain bleeds and swelling.
Seeking Alpha
Anavex: Despite Positive Spin, No Clarity On Anomalies
Thursday Jan 12 2023 at 10:49
Anavex Life Sciences Corp. presented solid-looking Alzheimer’s data last month. Critics found a number of anomalies, some more real than others.
Forbes
6 Favorite Biotech Bets For 2023
Monday Jan 09 2023 at 10:48
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation’s leading newsletter advisors. This year’s report is no exception; here’s a six-pack of favorite biotech ideas for the coming year.
The Motley Fool
Anavex Life Sciences Stock Could 5x Before 2025 — Here’s Why
Saturday Dec 17 2022 at 09:15
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
The Motley Fool
Is Anavex Life Sciences a Buy?
Tuesday Dec 13 2022 at 09:45
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer’s.
GlobeNewsWire
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Monday Dec 12 2022 at 07:00
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th 2023, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM – 08:55 AM (Pacific Time).
Seeking Alpha
Anavex Life Sciences: The Little Company That Did
Tuesday Dec 06 2022 at 12:51
Anavex’s 2-73/blarcamesine produced significant reductions in cognitive decline in early Alzheimer’s disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically significant.
Zacks Investment Research
Anavex’s (AVXL) Lead Alzheimer’s Drug Meets Study Goal
Monday Dec 05 2022 at 14:18
Top-line data from a phase IIb/III study shows that Anave’s (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer’s disease.
Anavex Life Sciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Anavex Life Sciences’s Altman Z-score is -1.62 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Anavex Life Sciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $2.14M of common stock in Anavex Life Sciences on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Anavex Life Sciences’s Current Ratio of 30.54 is greater than its Industry Group of 4.76 (541.6% greater)
Anavex Life Sciences’s Current Ratio of 30.54 is greater than its Major Industry Group of 4.32 (606.9% greater)
Anavex Life Sciences’s Current Ratio of 30.54 is greater than its Sector of 2.6 (1074.6% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.06 & -1.27)
Cannot compare a negative PE Ratio (-0.06 & -1.1)
Cannot compare a negative PE Ratio (-0.06 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Cannot compute a percentage difference when there are zeros in the calculation
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Anavex Life Sciences’s ROE of -0.08 is greater than its Industry Group of -0.44 (81.8% greater)
Anavex Life Sciences’s ROE of -0.08 is greater than its Major Industry Group of -0.38 (78.9% greater)
Anavex Life Sciences’s ROE of -0.08 is lower than its Sector of -0.03 (-166.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Anavex Life Sciences’s ROCE of -0.07 is greater than its Industry Group of -0.42 (83.3% greater)
Anavex Life Sciences’s ROCE of -0.07 is greater than its Major Industry Group of -0.37 (81.1% greater)
Anavex Life Sciences’s ROCE of -0.07 is lower than its Sector of -0.04 (-75.0% lower)
Derived from SEC.GOV filing dataopen_in_new